The 26 references in paper А. Добровольский Б., Е. Титаева В., Е. Яровая Б., А. Сторожилова Н., И. Трубачева А., В. Серебрякова Н., В. Кавешников С., Е. Панченко П. (2014) “Д-ДИМЕР, ФИБРИНОГЕН И УРОВЕНЬ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ. АНАЛИЗ ПОПУЛЯЦИИ ВЗРОСЛОГО НАСЕЛЕНИЯ ТОМСКА (ИССЛЕДОВАНИЕ ЭССЕ-РФ)” / spz:neicon:aterotromboz:y:2014:i:2:p:19-24

1
Kenet G, LЯtkhoff LK, Albisetti M et al. Meta-Analysis of Observational Studies Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies. Circulation,
(check this in PDF content)
2
10, 121: 1838-1847. 2 . Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a metaanalysis of published studies. Am Heart J., 2003, 146 (6): 948-57.
(check this in PDF content)
3
Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet,2006, 367: 651–8.
(check this in PDF content)
4
Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. European Heart Journal2004, 25: 1197–1207.
(check this in PDF content)
5
Lemkes BA, Hermanides J, DeVries JH, Holleman F, Meijers JCM, Hoekstra JBL. Hyperglycemia: a prothrombotic factor? J Thromb Haemost2010, 8: 1663–9.
(check this in PDF content)
6
Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008, 117: 224–30.
(check this in PDF content)
7
Kok MGM, Meijers JCM, Pinto-Sietsma S-J. Individuals with coronary artery disease at a young age and features of the metabolic syndrome have an increased prothrombotic potential. Thrombosis and Haemostasis2014, 111(3): 381-564.
(check this in PDF content)
8
Wilhelmsen L, SvКrdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984, 311 (8): 501-5.
(check this in PDF content)
9
Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med.1995, 332 (10): 635-41.
(check this in PDF content)
10
Undas A, Brummel-Ziedins KE, Potaczek DP, Stobierska-Dzierzek B, Bryniarski L, Szczeklik A, Mann KG. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost.2006,4: 2397–2404.
(check this in PDF content)
11
Ahimastos AA, Latouche C, Natoli AK, Reddy-luthmoodoo M, Golledge J, Kingwell BA. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication. Circ Res. 2014, 28,114(7): 1144-55.
(check this in PDF content)
12
Rajzer M, Wojciechowska W, Kawecka-Jaszcz K, Undas A. Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication. Thrombosis Research2012, 130: 99–103.
(check this in PDF content)
13
Добровольский А.Б., Титаева Е.В., Яровая Е.Б. и соав. Коагулогические факторы риска сердечно-сосудистых заболеваний в популяции взрослого населения Томска. Системные гипертензии, 2013, 10: 50-54.
(check this in PDF content)
14
Протокол многоцентрового наблюдательного исследования «Эпидемиология Сердечно-Сосудистых заболеваний в регионах Российской Федерации» ЭССЕ-РФ. М., 2012.
(check this in PDF content)
15
Stone MC, Thorp JM. Plasma fibrinogen — a major coronary risk factor. J R Coll Gen Pract. 1985, 35 (281): 565-9.
(check this in PDF content)
16
Assmann G, Cullen P, Schulte H. The MЯnster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998, 19 (Suppl A): A2-11.
(check this in PDF content)
17
Kaptoge S, Di Angelantonio E, Pennells L. The Emerging Risk Factors Collaboration. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. N Engl J Med.2012, 367 (14): 1310–1320.
(check this in PDF content)
18
Koenig W. Fibrin (ogen) in cardiovascular disease: an update. Thromb Haemost2003, 89: 601–9.
(check this in PDF content)
19
Di Nisio M, Squizzato A, Rutjes AWS, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost2007, 5: 296–304.
(check this in PDF content)
20
Catena C, Colussi G, Fedrizzi S, Sechi LA. Association of a prothrombotic state with left-ventricular diastolic dysfunction in hypertension: a tissue-Doppler imaging study. J Hypertens. 2013, 31(10):2077-84.
(check this in PDF content)
21
Di Castelnuovo A, de Curtis A, Costanzo S et al on behalf of the MOLI-SANI Project Investigators. Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. Haematologica2013, 98(9): 147680.
(check this in PDF content)
22
Willeit P, Thompson A, Aspelund T, Rumley A, Eiriksdottir G, et al. Hemostatic Factors and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Updated Meta-Analyses. PLoS ONE 2013, 8(2): e55175. doi:10.1371/journal.pone.0055175.
(check this in PDF content)
23
Undas A, Celinska-LЪwenhoff M, Domagala TB et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost2005, 94: 193-9.
(check this in PDF content)
24
Potaczek DP, Undas A, Iwaniec T, Szczeklik A. The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease. Thromb Haemost2005, 94: 224-5.
(check this in PDF content)
25
Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study. Atherosclerosis, 2009, 204: 273–275.
(check this in PDF content)
26
Cesari M, Kritchevsky SB, Atkinson HH, Penninx BW, Di Bari M, Tracy RP, Pahor M. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel
(check this in PDF content)